2024 discgenics duntsch The company's lead product candidate, IDCT, has been studied in several preclinical and clinical trials. In a Phase I/IIa clinical trial, IDCT was found to be safe and well-tolerated in patients with disc-related lower back pain. The trial also found that IDCT was able to reduce pain and improve function in these patients. Based on these results, the company is planning to conduct a larger, randomized, controlled clinical trial to further evaluate the safety and efficacy of IDCT in patients with disc-related lower back pain. In addition to IDCT, DiscGenics is also developing other regenerative cell-based therapies for degenerative diseases of the spine. These include therapies for spinal cord injury, degenerative disc disease, and facet joint osteoarthritis. The company is also exploring the use of its technology platform for other indications, such as osteoarthritis and cartilage repair. DiscGenics is a privately held company that was founded in 2007 and is based in Salt Lake City, Utah. The company has received funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also established partnerships with several academic and research institutions, including the University of California, San Diego, the University of Utah, and the University of Pittsburgh. In summary, DiscGenics is a clinical-stage regenerative medicine company that is focused on developing therapies for degenerative diseases of the spine. The company's lead product candidate, IDCT, is a homologous, allogeneic, injectable disc cell therapy that has been shown to be safe and well-tolerated in patients with disc-related lower back pain. The company is currently planning to conduct a larger, randomized, controlled clinical trial to further evaluate the safety and efficacy of IDCT in patients with disc-related lower back pain. In addition to IDCT, DiscGenics is also developing other regenerative cell-based therapies for degenerative diseases of the spine and is exploring the use of its technology platform for other indications.
The company's technology platform is based on adult pluripotent like stem cells (APLSCs), which are a type of stem cell that can differentiate into multiple cell types. These cells are derived from the patient's own disc tissue, and then expanded in the lab to create a large number of cells that can be used for therapy. The cells are then injected into the damaged disc, where they are intended to replace the damaged tissue and restore the normal function of the disc. The company's lead product candidate, IDCT, has been studied in several preclinical and clinical trials. In a Phase I/IIa clinical trial, IDCT was found to be safe and well-tolerated in patients with disc-related lower back pain. The trial also found that IDCT was able to reduce pain and improve function in these patients. Based on these results, the company is planning to conduct a larger, randomized, controlled clinical trial to further evaluate the safety and efficacy of IDCT in patients with disc-related lower back pain. In addition to IDCT, DiscGenics is also developing other regenerative cell-based therapies for degenerative diseases of the spine. These include therapies for spinal cord injury, degenerative disc disease, and facet joint osteoarthritis. The company is also exploring the use of its technology platform for other indications, such as osteoarthritis and cartilage repair. DiscGenics is a privately held company that was founded in 2007 and is based in Salt Lake City, Utah. The company has received funding from a number of sources, including venture capital firms, strategic partners, and government grants. The company has also established partnerships with several academic and research institutions, including the University of California, San Diego, the University of Utah, and the University of Pittsburgh. In summary, DiscGenics is a clinical-stage regenerative medicine company that is focused on developing therapies for degenerative diseases of the spine. The company's lead product candidate, IDCT, is a homologous, allogeneic, injectable disc cell therapy that has been shown to be safe and well-tolerated in patients with disc-related lower back pain. The company is currently planning to conduct a larger, randomized, controlled clinical trial to further evaluate the safety and efficacy of IDCT in patients with disc-related lower back pain. In addition to IDCT, DiscGenics is also developing other regenerative cell-based therapies for degenerative diseases of the spine and is exploring the use of its technology platform for other indications.
Copyright 2024 All Right Reserved By.